Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | USP1 | O94782 | 1/20 | 0.32 |
| ▸ | EED | O75530 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16023241 | 0.88 | PTPN11 (0.35) | PTPN11USP1 | |
| SCHEMBL11968527 | 0.86 | PTPN11 (0.37) | PTPN11EEDL3MBTL1BRD4 | |
| SCHEMBL15805493 | 0.85 | PTPN11 (0.44) | PTPN11L3MBTL1BRD4 | |
| SCHEMBL15805225 | 0.85 | PTPN11 (0.40) | PTPN11USP1EEDL3MBTL1BRD4 | |
| SCHEMBL11968501 | 0.84 | PTPN11 (0.39) | PTPN11EEDL3MBTL1BRD4 | |
| SCHEMBL11968473 | 0.82 | PTPN11 (0.37) | PTPN11EEDL3MBTL1BRD4 | |
| SCHEMBL11968450 | 0.81 | PTPN11 (0.40) | PTPN11EEDL3MBTL1BRD4 | |
| SCHEMBL31436019 | 0.81 | PTPN11 (0.46) | PTPN11EEDL3MBTL1BRD4 | |
| SCHEMBL1516665 | 0.81 | TSHR (0.44) | PTPN11EEDL3MBTL1BRD4 | |
| SCHEMBL11968522 | 0.80 | PTPN11 (0.38) | PTPN11EEDL3MBTL1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951062-B2 | Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951062-B2 | Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9890153-B2 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890153-B2 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160090382-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-03-31 | — | — | US | disclosed |
| US-20160090382-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-03-31 | — | — | US | disclosed |
| US-20160090382-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-03-31 | — | — | US | disclosed |
| US-20160081989-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| US-20160081989-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| US-20160081989-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| WO-2008124849-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080221119-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221119-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-7361763-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361763-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361764-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361764-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| WO-2007106236-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090382-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | SIK2, SIK1, SIK3 | PTPN11 508/4885USP1 4226/4885EED 3051/4885 |
| US-20080221119-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | MAP3K20, MAP4K2, MAP3K19 | PTPN11 582/4885USP1 2502/4885EED 2646/4885 |
| US-20160081989-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | SIK2, SIK1, SIK3 | PTPN11 508/4885USP1 4226/4885EED 3051/4885 |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | MAP3K20, MAP4K2, MAP3K6 | PTPN11 697/4885USP1 2900/4885EED 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.